KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Intangibles (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Intangibles for 15 consecutive years, with $293.6 million as the latest value for Q4 2024.

  • On a quarterly basis, Intangibles fell 8.4% to $293.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was $293.6 million, a 8.4% decrease, with the full-year FY2024 number at $293.6 million, down 8.4% from a year prior.
  • Intangibles was $293.6 million for Q4 2024 at Bio-Rad Laboratories, down from $307.3 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $332.1 million in Q4 2022 to a low of $138.3 million in Q1 2020.
  • A 5-year average of $271.7 million and a median of $300.5 million in 2024 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: surged 37.13% in 2023, then fell 8.4% in 2024.
  • Bio-Rad Laboratories' Intangibles stood at $199.5 million in 2020, then grew by 27.29% to $253.9 million in 2021, then skyrocketed by 30.78% to $332.1 million in 2022, then decreased by 3.49% to $320.5 million in 2023, then dropped by 8.4% to $293.6 million in 2024.
  • Per Business Quant, the three most recent readings for BIO's Intangibles are $293.6 million (Q4 2024), $307.3 million (Q3 2024), and $320.5 million (Q4 2023).